ArticleJournal of the European Academy of Dermatology and Venereology : JEADV2020
Baseline patient-reported outcomes from UNITE: an observational, international, multicentre registry to evaluate hidradenitis suppurativa in clinical practice.
Article in Journal of the European Academy of Dermatology and Venereology : JEADV, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 1 synthesis or guideline pooled it, 26 citations in OpenAlex.
- Short-term efficacy of biologics in moderate-to-severe hidradenitis suppurativa: A systematic review and NMA.Journal of the European Academy of Dermatology and Venereology : JEADV · 2026Pooled it
- Quality of Life in Patients with Hidradenitis Suppurativa: A Scoping Review.Nursing reports (Pavia, Italy) · 2026Review
- Palliative and Supportive Care Needs in Advanced Hidradenitis Suppurativa: A Systematic Review.Cureus · 2026Review
- Bimekizumab for the treatment of hidradenitis suppurativa.Immunotherapy · 2024Review
- Burden of Hidradenitis Suppurativa: A Systematic Literature Review of Patient Reported Outcomes.Dermatology and therapy · 2024Review
- Patient perspectives on diagnosis and management of hidradenitis suppurativa: A web-based survey.JAAD international · 2022Article
- Janus kinase 1 inhibitor INCB054707 for patients with moderate-to-severe hidradenitis suppurativa: results from two phase II studies.The British journal of dermatology · 2022Article
- [Need for real-world data studies on hidradenitis suppurativa/acne inversa treatment].Der Hautarzt; Zeitschrift fur Dermatologie, Venerologie, und verwandte Gebiete · 2021Review
- Quality of Life in Hidradenitis Suppurativa: An Update.International journal of environmental research and public health · 2021Review
- The measurement performance of the EQ-5D-5L versus EQ-5D-3L in patients with hidradenitis suppurativa.Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation · 2021Article
- Baseline Characteristics from UNITE: An Observational, International, Multicentre Registry to Evaluate Hidradenitis Suppurativa (Acne Inversa) in Clinical Practice.American journal of clinical dermatology · 2020Observational
- The most recent advances in understanding and managing hidradenitis suppurativa.F1000Research · 2020Review
- Learning from disease registries during a pandemic: Moving toward an international federation of patient registries.Clinics in dermatologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 6 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundHidradenitis suppurativa (HS) is a chronic, inflammatory, skin condition associated with many comorbidities and often has a substantial impact on patients' lives.
objectivesTo evaluate symptom burden and health-related quality of life (HRQoL) at baseline in patients with HS in an observational, real-world, clinical setting using several tools including a validated HS-specific instrument.
methodsThis study evaluated HRQoL data from the international UNITE HS disease registry. Administration of patient-reported outcome (PRO) instruments and collection of data were executed per local regulations. All data were assessed using descriptive statistical methods.
resultsPRO data from 529 adults and 65 adolescents were evaluated. Most adults (64.5%) and adolescents (73.8%) were classified as Hurley Stage II with substantial disease burden at baseline. HS had a large effect (mean DLQI = 12.6) and moderate effect (mean CDLQI = 6.9) on the lives of adults and adolescents, respectively. Approximately 58% of adults and 41% of adolescents had anxiety scores beyond the normal range; 30% of adults and 16% of adolescents exhibited symptoms of depression. Based on HSSA and HSIA scores, approximately 30% of adults reported a substantial burden of multiple HS clinical symptoms and more than 45% reported a significant emotional impact of HS that adversely affected their intimate relationships. Only 60% of adults were employed and of those, 64% reported at least some degree of impairment while working because of HS.
conclusionsBased on PROs collected from patients enrolled in the UNITE registry, a real-world, clinical setting, HS has a significant negative impact on the everyday lives of patients affected by this disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.